Paradigm Biopharmaceuticals Ltd
ASX:PAR

Watchlist Manager
Paradigm Biopharmaceuticals Ltd Logo
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Watchlist
Price: 0.39 AUD -2.5% Market Closed
Market Cap: 136.3m AUD
Have any thoughts about
Paradigm Biopharmaceuticals Ltd?
Write Note

Paradigm Biopharmaceuticals Ltd
Tax Provision

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Paradigm Biopharmaceuticals Ltd
Tax Provision Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Tax Provision CAGR 3Y CAGR 5Y CAGR 10Y
Paradigm Biopharmaceuticals Ltd
ASX:PAR
Tax Provision
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mesoblast Ltd
ASX:MSB
Tax Provision
$191k
CAGR 3-Years
-38%
CAGR 5-Years
-54%
CAGR 10-Years
N/A
CSL Ltd
ASX:CSL
Tax Provision
-$661m
CAGR 3-Years
-4%
CAGR 5-Years
-9%
CAGR 10-Years
-8%
Clinuvel Pharmaceuticals Ltd
ASX:CUV
Tax Provision
-AU$15m
CAGR 3-Years
-148%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Telix Pharmaceuticals Ltd
ASX:TLX
Tax Provision
AU$2.1m
CAGR 3-Years
-11%
CAGR 5-Years
2%
CAGR 10-Years
N/A
PYC Therapeutics Ltd
ASX:PYC
Tax Provision
AU$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Paradigm Biopharmaceuticals Ltd
Glance View

Market Cap
136.6m AUD
Industry
Biotechnology

Paradigm Biopharmaceuticals Ltd. is a biopharmaceutical company, engages in researching and developing therapeutic products for human use. The company is headquartered in Melbourne, Victoria. The company went IPO on 2015-08-19. The firm is developing and commercializing injectable Pentosan Polysulfate Sodium (PPS) for the treatment of pain associated with musculoskeletal disorders driven by injury, inflammation, aging, degenerative disease, infection, or genetic predisposition. The firm focuses on repurposing PPS for the treatment of Osteoarthritis (OA) and bone marrow lesions (BML), chronic heart failure (CHF) and alphaviral arthritis (Ross River Virus and Chikungunya). Its product candidate PPS is a non-opioid drug treatment for the chronic pain and joint stiffness of Osteoarthritis. Its product candidate PPS is providing treatment for Mucopolysaccharidosis, an inherited defect in the catabolism of sulfated components of connective tissue known as glycosaminoglycans (GAGs). Its product candidate PPS is used to treat Ross River virus and Chikungunya, an arthritogenic alphaviruses transmitted by mosquito bites.

PAR Intrinsic Value
0.43 AUD
Undervaluation 9%
Intrinsic Value
Price

See Also

Back to Top